↑ Rising
Business
Why Arrowhead Shot Sky-High, While Ionis Toppled
Arrowhead Pharmaceuticals shares surged following positive Phase 3 trial results for its lipid-lowering drug, impacting competitor Ionis.
Phase 3 Trials
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.